Grifols, S.A.

NASDAQ:GRFS

Drug Manufacturers - General

Healthcare
$8.47 +0.34%

+$0.03 today

Market cap
$7.17B
Beta
1.17
P/E (TTM)
14.7
EPS (TTM)
$0.61
Dividend yield
1.67%
52W Low $7.26High $11.14

Volume 0.59M

Average 0.69M

GRFS Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Grifols, S.A.NASDAQ: GRFS

Revenue · Q2 FY2026 · quarter ended Jun 2026

Revenue declines year over year

Q2 FY2026 revenue of €1.87B fell 0.9% year over year, behind the -0.2% change in trailing-twelve-month revenue. Sequentially, it rose 8.5% from the prior quarter. Over 3 fiscal years it compounded at +6.0% a year.

Context

  • Revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 4 analysts of €7.71B (+6.7%) for the fiscal year ending Dec 2026, a step up from the +0.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
€1.87B+8.5% QoQ
Last fiscal yearDec 2025
€7.23B+0.2% YoY
LTMJun 2026
€7.43B-0.2% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-0.9%+6.1%+7.1 pp
1 year+0.2%+6.7%+6.5 pp
3-year CAGR+6.0%+6.2%+0.2 pp
5-year CAGR+5.9%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

EUR · from the income statement

Latest · FY2025
7.23B EUR
Year-over-year change
+0.2%
4-year CAGR
+10.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How GRFS compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of -0.2% is the 6th highest of 9, against a peer median of +0.7%.
  • Over three fiscal years its annual growth of +6.0% compares with a peer median of +0.3%.
GRFS Competitors
Revenue for GRFS and competitors
Company Period LTM YoY 3-year CAGR
ABTAbbott LaboratoriesLTM Sep 2026$48.23B USD+10.0%+0.5%
BDXBecton, Dickinson and CompanyLTM Sep 2026$20.22B USD-7.4%+0.1%
GRFSGrifols, S.A.LTM Jun 2026€7.43B EUR-0.2%+6.0%
QDELQuidelOrtho CorporationLTM Mar 2026$2.66B USD-3.9%-5.8%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$2.59B USD+1.4%-2.7%
HAEHaemonetics CorporationLTM Jun 2026$1.35B USD+0.4%+4.5%
TECHBio-Techne CorporationLTM Sep 2026$1.23B USD+0.9%+2.2%
ADMAADMA Biologics, Inc.LTM Jun 2026$512.28M USD+8.0%+49.0%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026$208.78M USD-3.3%-40.5%
Peer median (excluding GRFS) —+0.7%+0.3%

Competitors are the stored peer set for GRFS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.93B6.06B6.59B7.21B7.23B
Cost of Revenue2.97B3.85B4.11B4.42B4.65B
Gross Profit1.96B2.21B2.48B2.79B2.58B
Gross Margin39.8%36.5%37.7%38.7%35.7%
Research & Development354.88M361.14M395.28M384.04M358.28M
Selling, General & Admin1.06B1.11B1.27B1.14B1.02B
Operating Expenses1.37B1.43B1.7B1.6B1.39B
Depreciation & Amortization359.77M410.98M446.42M437.9M432.24M
EBITDA944.03M1.19B1.17B1.48B1.62B
EBITDA Margin19.1%19.7%17.7%20.6%22.5%
Operating Income595.06M782.44M782.32M1.19B1.19B
Operating Margin12.1%12.9%11.9%16.5%16.4%
Interest Income11.55M33.86M62.43M48.05M32.66M
Interest Expense233.81M444.54M516.06M773.16M600.33M
Other Income / Expenses(244.61M)(444.42M)(575.3M)(748.02M)(596.49M)
Income Before Tax350.45M338.01M207.02M444M590.73M
Pre-Tax Margin7.1%5.6%3.1%6.2%8.2%
Income Tax Expense85.13M90.11M43.35M231.19M110.46M
Net Income188.73M185.04M42.32M156.92M386.13M
Net Margin3.8%3.1%0.6%2.2%5.3%
EPS (Basic)0.270.310.090.230.57
EPS (Diluted)0.270.310.090.230.57
Weighted Avg Shares681.56M679.81M679.76M680.02M680.58M
Weighted Avg Shares (Diluted)681.56M679.81M679.76M680.02M680.58M

Grifols, S.A.

NASDAQ:GRFS

Intrinsic Alpha fair value

Locked

Current Price

$8.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.